Emergent BioSolutions (EBS) Cash & Equivalents (2010 - 2026)

Emergent BioSolutions' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $160.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 7.51% year-over-year to $160.3 million; the TTM figure through Mar 2026 stood at $160.3 million (up 7.51% YoY), while the FY2025 annual figure was $205.4 million, up 106.43% from the prior year.
• Cash & Equivalents was $160.3 million for Q1 2026 at Emergent BioSolutions, down from $205.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $642.6 million in Q4 2022 to a low of $69.7 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $224.8 million across 5 years, with a median of $160.3 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 82.62% in 2023, then surged 283.5% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $642.6 million in 2022, then plunged by 82.62% to $111.7 million in 2023, then declined by 10.92% to $99.5 million in 2024, then surged by 106.43% to $205.4 million in 2025, then fell by 21.96% to $160.3 million in 2026.
• The last three Cash & Equivalents figures came in at $160.3 million (Q1 2026), $205.4 million (Q4 2025), and $245.5 million (Q3 2025), per Business Quant data.